# Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

> **NCT02081755** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Baylor Research Institute** · enrollment: 336 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Tacrolimus
- **DRUG:** Myfortic
- **DRUG:** CellCept
- **DRUG:** Imuran

## Key facts

- **NCT ID:** NCT02081755
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2014-03
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081755, "Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02081755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*